{"entity":{"id":"paper-crizotinib-paediatric-alcl-imt-jco-2017","kind":"paper","name":"Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study","aka":["Mossé 2017","ADVL0912"],"tldr":"Crizotinib produced responses in 83 to 90 per cent of children with relapsed ALK-positive anaplastic large cell lymphoma, most of them complete.","summary":"A Children's Oncology Group study of the ALK inhibitor crizotinib given by mouth twice daily to 26 patients with relapsed or refractory ALK-positive anaplastic large cell lymphoma and 14 with metastatic or inoperable ALK-positive inflammatory myofibroblastic tumour, with serial measurement of NPM-ALK fusion transcripts in ALCL.","asOf":"2026-11-03","links":[{"label":"Journal of Clinical Oncology 2017","url":"https://doi.org/10.1200/JCO.2017.73.4830"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/28787259/"},{"label":"Europe PMC","url":"https://europepmc.org/article/MED/28787259"}],"tags":["lymphoma-evidence-entities"],"related":[],"cancers":["alk-positive-anaplastic-large-cell-lymphoma","inflammatory-myofibroblastic-tumour"],"sections":[],"technologies":[],"targets":["alk"],"drugs":["crizotinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["advl0912-crizotinib"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"journal":"Journal of Clinical Oncology","year":2017,"doi":"10.1200/JCO.2017.73.4830","pmid":"28787259","authors":"Mossé YP, Voss SD, Lim MS, et al.","paperType":"observational","findings":["In ALCL, overall response was 83 per cent at 165 mg/m2 and 90 per cent at 280 mg/m2.","Complete response was seen in five of six patients at 165 mg/m2 and 16 of 20 at 280 mg/m2.","In inflammatory myofibroblastic tumour, overall response was 86 per cent and complete response 36 per cent (five of 14).","Neutrophil count decrease was the commonest drug-related adverse event: 33 and 70 per cent in the two ALCL dose groups, 43 per cent in IMT.","12 patients stopped protocol therapy to proceed to transplant."],"whatItMeans":"The evidence behind the statement on the ALK-positive ALCL page that ALK inhibitors produce responses and are used especially in children and young adults.","caveats":["Single arm, 26 patients with ALCL.","Children and young people only."],"participants":40},"route":"/key-papers/paper-crizotinib-paediatric-alcl-imt-jco-2017/","neighbours":{"cancer":[{"id":"alk-positive-anaplastic-large-cell-lymphoma","kind":"cancer","name":"ALK-positive anaplastic large cell lymphoma","route":"/cancers/alk-positive-anaplastic-large-cell-lymphoma/"},{"id":"inflammatory-myofibroblastic-tumour","kind":"cancer","name":"Inflammatory myofibroblastic tumour (IMT)","route":"/cancers/inflammatory-myofibroblastic-tumour/"}],"target":[{"id":"alk","kind":"target","name":"ALK","route":"/targets/alk/"}],"drug":[{"id":"crizotinib","kind":"drug","name":"Crizotinib","route":"/drugs/crizotinib/"}],"trial":[{"id":"advl0912-crizotinib","kind":"trial","name":"COG ADVL0912: crizotinib in children with ALK-driven tumours","route":"/trials/advl0912-crizotinib/"}]}}